BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

  Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.

  November 1, 2023

   · 

  20 min read
• Business

  Bouwien Smits Joins Civica Rx as Site Vice President and General Manager of New Virginia Manufacturing Facility

  Civica Inc. is proud to announce that pharmaceutical industry leader Bouwien Smits has joined Civica as the new Site Vice President and General Manager of the company’s new sterile injectable manufacturing facility.

  November 1, 2023

   · 

  2 min read
• Deals

  Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

  Ligand Pharmaceuticals Incorporated announced that it has acquired Tolerance Therapeutics, Inc. for $20 million in cash.

  November 1, 2023

   · 

  5 min read
• Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023

  Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.

  November 1, 2023

   · 

  4 min read
• Business

  CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

  CureVac N.V. today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.

  November 1, 2023

   · 

  6 min read
• Drug Development

  Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study

  Ashvattha Therapeutics today announced that the first patient has been dosed with D-4517.2, a subcutaneously administered anti-angiogenic therapeutic, in a Phase 2 chronic dosing study. The open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet AMD and DME.

  November 1, 2023

   · 

  4 min read
• Alpha Tau to Participate in November 2023 Investor Conferences

  Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that management will participate in the following investor conferences in November 2023.

  November 1, 2023

   · 

  1 min read
• Zymeworks Announces Participation in Upcoming Investor Conferences - November 1, 2023

  Zymeworks Inc. today announced that management will participate in the following upcoming investor conferences.

  November 1, 2023

   · 

  2 min read
• Pharm Country

  BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI

  BioSig Technologies, Inc. announced that the U.S. Patent and Trademark Office has awarded several new utility patents covering the Company’s PURE EP™ digital signal processing technology.

  November 1, 2023

   · 

  5 min read
• Business

  Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

  Eterna Therapeutics Inc. today announced the appointment of James Bristol, Ph.D., to its Board of Directors.

  November 1, 2023

   · 

  4 min read